The Latest News on Sparsentan (Sparsentan): Drug Progress and Market Dynamics in 2025

As of2025, the pharmaceutical progress and market dynamics of Sparsentan (Sparsentan, trade name: FILSPARI) continue to develop globally. The drug was developed by Travere Therapeutics and is mainly used to treat primary IgA nephropathy (IgAN) and focal segmental tubulosclerosis (FSGS). Here are the latest developments:

2024In September2024, the US FDA approved sparsentane for the treatment of adult patients with IgAN, marking the official launch of the drug in the US market. According toTravere Therapeutics Company2024 fourth quarter financial report, FILSPARI’s net sales reached 49.6 million million, a year-on-year increase of 40%. By the end of 2024, the company expects full-year sales to be approximately 227USD, demonstrating strong market demand and patient acceptance.

In Europe, FILSPARIobtained conditional marketing authorization from the European Commission in 20244month (CMA), suitable for adult patients with primary IgAN whose urinary protein excretion is ≥1.0g/days. The license applies to all EU member states as well as Iceland, Liechtenstein and Norway. Travere Therapeuticsand partners CSL Vifor have launched drug launches in countries such as Germany, Austria and Switzerland. It is expected that FILSPARI will be fully approved in Europe in 2025.

In Japan, Travere Therapeutics and Renalys PharmaThe company reached an exclusive license agreement in January 2024 to introduce FILSPARI to Japan and other Asian countries. Renalys Pharmalaunched the registration of FILSPARI in Japan in the second quarter of 2024 pan>III phase clinical trial, and announced the completion of patient enrollment in January 2025. The research results on urine protein/creatinine ratio (UP/C) are expected to be available in the second half of 2025 to provide support for submission of marketing applications to the Japan Pharmaceuticals and Medical Devices Agency (PMDA).

Currently, FILSPARI has not been launched in China, so patients cannot purchase it directly in China. According to the price information from overseas channels, the original version of FILSPARI is more expensive, with each box selling for approximately 4.5 to 5 RMB. In comparison, the imitation version produced in Laos offers a more economical option, priced at approximately 7,000 to 8,000 yuan per box. However, due to exchange rate fluctuations and different import channels, specific prices may change, and the above prices are for reference only.

To sum up, the global launch of Sparsentan is progressing smoothly and market demand continues to grow. Although it is not yet available in China, patients can obtain the drug through overseas channels, but they need to pay attention to price differences and channel selection. With the approval and marketing in more countries in the next few years, sparsentan is expected to become one of the important drugs for the treatment of IgAN and FSGS.

Reference materials:https://www.sparsentan.com/